NVL-655 Market Summary

Key Factors Driving NVL-655 Growth

1. Strong activity in heavily pretreated ALK-positive NSCLC: The most important growth driver is the positive Phase I/II ALKOVE-1 data. Among 253 TKI-pretreated patients, including patients who had received a median of three prior lines of therapy, neladalkib achieved a 31% objective response rate (ORR) by blinded independent central review. Importantly, 64% of responders remained in response at 12 months and 53% at 18 months. In the particularly difficult lorlatinib-naïve subgroup, ORR reached 46%, with 80% and 60% of responses maintained at 12 and 18 months, respectively.

2. Potential to address ALK resistance mutations that limit existing TKIs: Resistance mutations are a major unmet need in ALK-positive NSCLC. In ALKOVE-1, 19% of the pivotal population had a secondary ALK G1202R mutation and 17% had compound ALK resistance mutations. Neladalkib produced a particularly strong 68% ORR in patients with G1202R, increasing to 83% among lorlatinib-naïve patients with G1202R. Preclinical work also showed ≥100-fold improved potency against ALK G1202R single and compound mutations compared with approved ALK TKIs.

3. Meaningful CNS activity could provide a major competitive advantage: Brain metastases are common in ALK-positive NSCLC, and approximately 40% of patients in the pivotal pretreated ALKOVE-1 population had active CNS disease at baseline. Among 92 patients with measurable CNS lesions, neladalkib achieved an intracranial ORR of 32%, while the lorlatinib-naïve subgroup achieved 63% intracranial ORR. Importantly, intracranial responses were also observed in patients previously treated with lorlatinib. The drug's brain penetration and CNS activity could therefore support differentiation in a clinically important segment.

4. Potential expansion into the first-line ALK-positive NSCLC market: The commercial opportunity could expand substantially if neladalkib demonstrates superiority or non-inferiority to established first-line therapy. Preliminary data from 44 TKI-naïve patients showed an 86% ORR, with 91% of responders maintaining response for at least 12 months. Intracranial ORR was 78% (7/9), with no CNS progression among responders at the data cutoff. These results are being tested in the ongoing ALKAZAR Phase III trial, which directly compares neladalkib with alectinib in treatment-naïve ALK-positive advanced NSCLC.

5. Potentially differentiated tolerability through ALK selectivity/TRK sparing: Neladalkib was deliberately designed to inhibit ALK while minimizing off-target TRK inhibition, which Nuvalent believes may help address CNS and tolerability issues associated with some existing ALK TKIs. In the 656 patients treated at the recommended Phase II dose, only 5% discontinued treatment because of treatment-emergent adverse events, while 17% required dose reductions. The most common adverse events were mainly laboratory transaminase elevations, constipation, dysgeusia, peripheral edema, cough and nausea.

NVL-655 Recent Developments

In May 2026, the FDA accepted the neladalkib NDA for filing and granted Priority Review, with a November 27, 2026 PDUFA date. More importantly, GSK completed its acquisition of Nuvalent in July 2026 for approximately $10.6 billion, gaining neladalkib and zidesamtinib. GSK described neladalkib as a potential best-in-class asset with multi-blockbuster potential and expects both lead assets to contribute to revenue growth from 2027 if approved.

“NVL-655 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of NVL-655 for potential indication like Non-small cell lung cancer and Solid tumours in the 7MM. A detailed picture of NVL-655’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the NVL-655 for potential indications. The NVL-655 market report provides insights about NVL-655’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current NVL-655 performance, future market assessments inclusive of the NVL-655 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of NVL-655 sales forecasts, along with factors driving its market.

NVL-655 Drug Summary

NVL-655, now known as Neladalkib, is an investigational, next-generation, orally administered, brain-penetrant and highly selective anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) developed by Nuvalent for the treatment of ALK-positive non-small cell lung cancer (NSCLC). The drug is rationally designed to inhibit ALK and a broad range of treatment-emergent resistance mutations, including single and compound mutations involving G1202R, while sparing the structurally related tropomyosin receptor kinase (TRK) family to potentially reduce TRK-related central nervous system (CNS) adverse effects. Neladalkib is being developed to address both systemic and CNS disease, including tumors that have progressed following first-, second-, and third-generation ALK inhibitors. In clinical development, the recommended Phase II dose was established at 150 mg once daily, and early ALKOVE-1 data demonstrated durable systemic and intracranial responses in heavily pretreated patients. As of 2026, the drug has received FDA Breakthrough Therapy and Orphan Drug designations for ALK-positive NSCLC, while its New Drug Application for previously treated advanced ALK-positive NSCLC has been accepted for Priority Review with a PDUFA target action date of November 2026; a Phase III ALKAZAR trial is also evaluating neladalkib against alectinib in treatment-naïve ALK-positive advanced NSCLC. The report provides NVL-655’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the NVL-655 Market Report

The report provides insights into:

• A comprehensive product overview including the NVL-655 MoA, description, dosage and administration, research and development activities in potential indication like Non-small cell lung cancer and Solid tumours.
• Elaborated details on NVL-655 regulatory milestones and other development activities have been provided in NVL-655 market report.
• The report also highlights NVL-655‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The NVL-655 market report also covers the patents information, generic entry and impact on cost cut.
• The NVL-655 market report contains current and forecasted NVL-655 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The NVL-655 market report also features the SWOT analysis with analyst views for NVL-655 in potential indications.

Methodology

The NVL-655 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NVL-655 Analytical Perspective by DelveInsight

• In-depth NVL-655 Market Assessment

This NVL-655 sales market forecast report provides a detailed market assessment of NVL-655 for potential indication like Non-small cell lung cancer and Solid tumours in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted NVL-655 sales data uptil 2034.

• NVL-655 Clinical Assessment

The NVL-655 market report provides the clinical trials information of NVL-655 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

NVL-655 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

NVL-655 Market Potential & Revenue Forecast

• Projected market size for the NVL-655 and its key indications
• Estimated NVL-655 sales potential (NVL-655 peak sales forecasts)
• NVL-655 Pricing strategies and reimbursement landscape

NVL-655 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• NVL-655 Market positioning compared to existing treatments
• NVL-655 Strengths & weaknesses relative to competitors

NVL-655 Regulatory & Commercial Milestones

• NVL-655 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

NVL-655 Clinical Differentiation

• NVL-655 Efficacy & safety advantages over existing drugs
• NVL-655 Unique selling points

NVL-655 Market Report Highlights

• In the coming years, the NVL-655 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The NVL-655 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NVL-655’s dominance.
• Other emerging products for Non-small cell lung cancer and Solid tumours are expected to give tough market competition to NVL-655 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NVL-655 in potential indications.
• Analyse NVL-655 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted NVL-655 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of NVL-655 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of NVL-655? How strong is NVL-655’s clinical and commercial performance?
• What is NVL-655’s clinical trial status in each individual indications such as Non-small cell lung cancer and Solid tumours and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NVL-655 Manufacturers?
• What are the key designations that have been granted to NVL-655 for potential indications? How are they going to impact NVL-655’s penetration in various geographies?
• What is the current and forecasted NVL-655 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of NVL-655 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to NVL-655 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is NVL-655? What is the duration of therapy and what are the geographical variations in cost per patient?